Jesse Dovich, MD, Wins Tesla at 2017 ASCRS Meeting

May 8, 2017: By Market Scope
Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting.

Jesse Dovich, MD (right), winner of the Tesla at the 2017 ASCRS meeting. (Photo by Katie Cannady)

 

Ophthalmologist Jesse Dovich, MD, of Upland, California, was the winner of this year’s drawing for a Tesla electric car at the ASCRS annual meeting in Los Angeles.

The drawing was held May 8 at the ASCRS Exhibit Hall.

Dovich won a 2017 sapphire blue Model S.

He practices at the Pacific Eye Institute and Laser Center, with several locations in California, and is a clinical instructor with the Department of Ophthalmology at Loma Linda University.

In 2015, Thomas Carter, MD, of Ponca City, OK, won the ASCRS’ initial drawing for a 2015 red Tesla Model S at the meeting in San Diego.

In 2016, David Russell Brear, MD, of Culpeper, VA, was the winner of a blue Tesla Model S at the annual meeting in New Orleans.

This year’s drawing was available to conference attendees who obtained specially numbered tickets from exhibitors or ASCRS officials.

Attendees also could gain a ticket by contributing to the ASCRS Foundation or completing the ASCRS clinical survey.

Dovich’s ticket was the first one drawn.

 

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles.

A crowd forms May 8 at the Exhibit Hall for the drawing of a Tesla Model S at the 2017 ASCRS meeting in Los Angeles. (Photo by Tony Ingenito)

 

Tesla winner Jesse Dovich after the drawing

Tesla winner Jesse Dovich, MD, after the drawing. (Photo by Katie Cannady)

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022